Tarsus Pharmaceuticals Inc expected to post a loss of 92  cents a share - Earnings Preview

Tarsus Pharmaceuticals

06/05/2022 13:36

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 6 (estimated). 
    * The Irvine California-based  company is expected to report
 a
93.4% decrease in revenue to $2.2 million from $33.43 million a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Tarsus
Pharmaceuticals
Inc is for a loss of 92 cents per share. For the same quarter
last year, the company reported earnings of 47 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $62​, above​ its last closing price
of $12.05. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.76       -0.73      -0.72     Beat    1
 Sep. 30 2021  -0.41       -0.43      -0.76     Missed  -75.1
 Jun. 30 2021  -0.40       -0.48      0.33      Beat    169.2​
 Mar. 31 2021  -0.73       -0.64      0.47      Beat    173.4
 ​​Dec.                    -0.66      -0.68     Missed  -3
 31 2020                                                
 Sep. 30 2020  -0.53       -0.53      -3.71     Missed  -600​
 This summary was machine generated May 6 at 12:36 GMT.  All
figures in US dollars  unless otherwise stated